Abstract 24P
Background
Epigenome-wide association studies showed association of the peripheral blood methylation profile with potential immunological aspects such as systemic inflammation in various diseases. Since inflammation is recognized as hallmark in cancer development and progression, DNA methylation profiles of peripheral blood cells may serve as a personalized biomarker in oncology. Here, we aim to explore if the blood DNA methylation signature changes over time in patients with NSCLC treated with immune checkpoint inhibitors.
Methods
Patients diagnosed with treatment-naive metastatic NSCLC at our institution between March 2019 and December 2023 were included. Leukocyte DNA was collected and isolated prior to treatment initiation (BL) and at first restaging (1FU). Methylation analysis was performed with Infinium Methylation EPICv2.0 microarrays. Treatment response was analyzed by a board-certified radiologist according to iRECIST 1.1 and RANO 1.0 criteria.
Results
Forty-one patients (63% males, 37% females; median age 64 years, range 45-83) were analyzed: 32/41 (78%) adenocarcinoma, 6/41 (15%) squamous cell carcinoma, 2/41 (5%) adenosquamous and 1/41 (2%) pleomorphic carcinoma. Chemoimmunotherapy was administered in 31/41 (75.6%) and ICI monotherapy in 10/42 (24.4%) patients. Except one patient who received atezolizumab (PDL-1) all other received pembrolizumab (98%, PD-1). Median days between BL and 1FU was 63 (range 38-214) or 3 cycles of ICI (range 1-6). Of the included patients, 15/41 (36.6%) were classified as responder (iCR or iPR) and 26/41 (63.4%) as non-responder (iSD or iCPD) at first restaging. Durable clinical benefit (disease control > 6 months) was achieved in 28/41 (68.3%) patients. Based on the 500 most differentially methylated CpG sites in their blood DNA methylation profiles we could not demonstrate differences between BL and 1FU.
Conclusions
In our analysis, the blood methylation profile of patients with NSCLC was stable between baseline and follow up, implying that the blood DNA methylation profile is a stabile biomarker not influenced by therapy. Further analysis of the correlation with treatment response are currently ongoing.
Legal entity responsible for the study
The authors.
Funding
The financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association is gratefully acknowledged.
Disclosure
M. Preusser: Financial Interests, Personal and Institutional, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Lehrman Group (GLG), CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Boehringer Ingelheim, Telix Medscape, OncLive; Financial Interests, Personal and Institutional, Advisory Role: Gerson. A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, CeCaVa, Seagen, Alexion, Servier; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche; Non-Financial Interests, Personal, Leadership Role, Board Member: European Association of Neuro-Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
Resources:
Abstract
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
Resources:
Abstract
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
Resources:
Abstract
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
Resources:
Abstract
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
Resources:
Abstract
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
Resources:
Abstract
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
Resources:
Abstract
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
Resources:
Abstract
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session
Resources:
Abstract
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract